Neurogene's gene therapy NGN-401 cleared to enter clinic for Rett syndrome
Jan. 24, 2023
Neurogene Inc. has received FDA clearance of its IND application for NGN-401 for the treatment of Rett syndrome. The company plans to initiate a phase I/II trial in female pediatric patients with Rett syndrome this year.